相关实验视频
Updated: Jun 22, 2025

12:08
Improving IV Insulin Administration in a Community Hospital
Published on: June 11, 2012
18.8K
跨专业工作手册对于人工胰腺外科手术前血糖控制的有用性
Kiyo Mibu1,2, Hiroyuki Kitagawa3, Tsutomu Namikawa3
1Department of Nursing, Kochi Medical School, Nankoku, Japan.
Artificial organs
|July 4, 2024
概括
一本专业间的工作手册显著减少了术后血糖控制期间人工胰腺治疗中断时间. 这本手册改善了持续血液采样失败的管理,提高了患者的护理.
科学领域:
- 医疗器械 医疗器械
- 内分泌学 在内分泌学.
- 手术护理 手术护理
背景情况:
- 人工胰腺 (AP) 系统提供持续的葡萄糖监测和胰岛素输送,用于外科手术期间的血糖控制.
- 由于持续血液采样 (CBS) 失败而导致的治疗中断是AP使用的一个重大挑战.
- 制定了一份跨专业的工作手册,以解决CBS故障并最大限度地减少AP治疗停机时间.
研究的目的:
- 评估跨专业工作手册在减少由CBS失败引起的AP治疗中断方面的有效性.
- 评估手册对外科手术期间血糖控制管理的影响.
主要方法:
- 该手册详细介绍了专业角色,CBS故障管理协议和专业间转移检查点.
- 一项比较研究分析了手动实施前和手动实施后两年AP治疗和中断数据.
- 在两组之间比较了患者人口统计和血液损失.
主要成果:
- 在"After"组显示显著减少血流 (1164比366毫升).
- 平均AP治疗中断时间从34分钟减少到8分钟 (p=0.078).
- 每次中断的时间从24分钟显著减少到4分钟 (p<0.001).
结论:
- 跨专业工作手册在尽量减少AP治疗中断方面被证明是有效的.
- 实施标准化协议提高了外科手术期间葡萄糖管理AP系统的可靠性.
相关概念视频
Diabetes: Management and Pharmacotherapy
256
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
256
Hypoglycemia and Glucagon
254
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
254
Glucose Homeostasis: Pancreatic Islets and Insulin Secretion
1.2K
The pancreatic islets comprising only 1%-2% of the volume are highly vascularized and innervated mini-organs. They contain five endocrine cell types, including β cells that secrete insulin, which is synthesized as a single polypeptide chain, preproinsulin, processed to proinsulin, and finally to insulin and C-peptide. This process is complex and regulated, involving the Golgi complex, the endoplasmic reticulum, and the secretory granules of the β cell.
Insulin and C-peptide are...
Insulin and C-peptide are...
1.2K
Hormones Regulating Blood Glucose
3.2K
Insulin is released by beta cells of the pancreas when blood glucose levels are high. It facilitates glucose absorption and utilization in insulin-dependent cells with insulin receptors on their plasma membranes. Insulin promotes glucose uptake by increasing the number of glucose transport proteins in the cell membrane, allowing glucose to enter the cell. As a result, glucose utilization and ATP production are enhanced.
In addition to accelerating glucose uptake and utilization, insulin has...
In addition to accelerating glucose uptake and utilization, insulin has...
3.2K
Acute Pancreatitis II: Clinical Manifestations and Management
118
Acute pancreatitis presents a complex medical emergency characterized by rapid onset inflammation of the pancreas, demanding timely diagnosis and management to prevent complications. The condition primarily manifests through severe upper abdominal pain that often radiates to the back. This pain intensifies following the consumption of fatty foods. Accompanying symptoms such as nausea, vomiting, abdominal distention, fever, dyspnea, cyanosis, and jaundice can vary in intensity but significantly...
118
Oral Hypoglycemic Agents: Glinides
152
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
152

